182 related articles for article (PubMed ID: 30008907)
1. Association between EGFR/KRAS mutation and expression of VEGFA, VEGFR and VEGFR2 in lung adenocarcinoma.
Yuan XH; Yang J; Wang XY; Zhang XL; Qin TT; Li K
Oncol Lett; 2018 Aug; 16(2):2105-2112. PubMed ID: 30008907
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor and KRAS mutations in lung adenocarcinoma: a retrospective study of the Lebanese population.
Fakhruddin N; Mahfouz R; Farhat F; Tfayli A; Abdelkhalik R; Jabbour M; Yehia L; Mahfoud Z; Zaatari G
Oncol Rep; 2014 Nov; 32(5):2223-9. PubMed ID: 25120214
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome of epidermal growth factor receptor-tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations.
Zhang H; Bai H; Yang X; Zhong J; An T; Zhao J; Wang J
Thorac Cancer; 2016 Jan; 7(1):24-31. PubMed ID: 26813477
[TBL] [Abstract][Full Text] [Related]
4. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
5. Expression and localization of vascular endothelial growth factor A (VEGFA) and its two receptors (VEGFR1/FLT1 and VEGFR2/FLK1/KDR) in the canine corpus luteum and utero-placental compartments during pregnancy and at normal and induced parturition.
Gram A; Hoffmann B; Boos A; Kowalewski MP
Gen Comp Endocrinol; 2015 Nov; 223():54-65. PubMed ID: 26414127
[TBL] [Abstract][Full Text] [Related]
6. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung.
Jia XL; Chen G
Lung Cancer; 2011 Dec; 74(3):396-400. PubMed ID: 21592614
[TBL] [Abstract][Full Text] [Related]
7. EGFR fluorescence in situ hybridization-positive lung adenocarcinoma: incidence of coexisting KRAS and BRAF mutations.
Chiosea S; Shuai Y; Cieply K; Nikiforova MN; Dacic S
Hum Pathol; 2010 Aug; 41(8):1053-60. PubMed ID: 20381121
[TBL] [Abstract][Full Text] [Related]
8. Dual blockade of VEGFR1 and VEGFR2 by a novel peptide abrogates VEGF-driven angiogenesis, tumor growth, and metastasis through PI3K/AKT and MAPK/ERK1/2 pathway.
Sadremomtaz A; Mansouri K; Alemzadeh G; Safa M; Rastaghi AE; Asghari SM
Biochim Biophys Acta Gen Subj; 2018 Dec; 1862(12):2688-2700. PubMed ID: 30251659
[TBL] [Abstract][Full Text] [Related]
9. Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Holzer TR; Fulford AD; Reising LO; Nedderman DM; Zhang X; Benjamin LE; Schade AE; Nasir A
Anticancer Res; 2016 Jul; 36(7):3277-88. PubMed ID: 27354584
[TBL] [Abstract][Full Text] [Related]
10. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.
Cai G; Wong R; Chhieng D; Levy GH; Gettinger SN; Herbst RS; Puchalski JT; Homer RJ; Hui P
Cancer Cytopathol; 2013 Sep; 121(9):500-7. PubMed ID: 23495083
[TBL] [Abstract][Full Text] [Related]
11. The Evaluation of Vascular Endothelial Growth Factor A (VEGFA) and VEGFR2 Receptor as Prognostic Biomarkers in Bladder Cancer.
El Azzouzi M; El Ahanidi H; Hafidi Alaoui C; Chaoui I; Benbacer L; Tetou M; Hassan I; Bensaid M; Oukabli M; Ameur A; Al Bouzidi A; Attaleb M; El Mzibri M
Diagnostics (Basel); 2023 Apr; 13(8):. PubMed ID: 37189572
[TBL] [Abstract][Full Text] [Related]
12. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
13. The expression of
Jia X; Qian R; Zhang B; Zhao S
J Thorac Dis; 2016 Oct; 8(10):2682-2688. PubMed ID: 27867542
[TBL] [Abstract][Full Text] [Related]
14. FOXK2 transcriptionally activating VEGFA induces apatinib resistance in anaplastic thyroid cancer through VEGFA/VEGFR1 pathway.
Feng H; Jin Z; Liang J; Zhao Q; Zhan L; Yang Z; Yan J; Kuang J; Cheng X; Qiu W
Oncogene; 2021 Oct; 40(42):6115-6129. PubMed ID: 34489549
[TBL] [Abstract][Full Text] [Related]
15. Postrecurrence survival of surgically resected pulmonary adenocarcinoma patients according to
Ohtaki Y; Shimizu K; Kakegawa S; Nagashima T; Nakano T; Atsumi J; Enokida Y; Igai H; Ibe T; Sugano M; Kamiyoshihara M; Kawashima O; Kaira K; Sunaga N; Takeyoshi I
Mol Clin Oncol; 2014 Mar; 2(2):187-196. PubMed ID: 24649331
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
17. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
[TBL] [Abstract][Full Text] [Related]
18. EGFR, KRAS and ROS1 variants coexist in a lung adenocarcinoma patient.
Ju L; Han M; Zhao C; Li X
Lung Cancer; 2016 May; 95():94-7. PubMed ID: 27040858
[TBL] [Abstract][Full Text] [Related]
19. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.
Monaco SE; Nikiforova MN; Cieply K; Teot LA; Khalbuss WE; Dacic S
Hum Pathol; 2010 Jan; 41(1):94-102. PubMed ID: 19740513
[TBL] [Abstract][Full Text] [Related]
20. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
